Non-adherence to statin therapy: a major challenge for preventive cardiology

被引:117
作者
Bates, T. R. [1 ]
Connaughton, V. M. [1 ]
Watts, G. F. [1 ]
机构
[1] Univ Western Australia, Royal Perth Hosp, Lipid Disorders Clin, Dept Internal Med,Sch Med & Pharmacol, Perth, WA 6847, Australia
关键词
adherence; cardiovascular disease; economic cost; psychology; statin intolerance; statins; CORONARY-HEART-DISEASE; MEDICATION ADHERENCE; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; RISK-FACTORS; FOLLOW-UP; CHOLESTEROL; IMPACT; PRESCRIPTION;
D O I
10.1517/14656560903376186
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Hypercholesterolemia is a major risk factor for atherosclerosis and cardiovascular disease, the leading cause of death worldwide. in the last twenty years, effective lipid-lowering therapies, particularly statins, have become widely available to prevent and reverse the progression of disease. However, there is a significant gap between expected and actual benefits; this may be attributed to poor adherence to statin therapy. Objective: To define the extent, causes (including psychological aspects), consequences and management of non-adherence to statins. Methods: Literature using PubMed and Medline up to and including 30 July 2009. Results: Adherence to statin therapy is suboptimal in both primary and secondary prevention of cardiovascular disease. Causes vary, and include patient factors (e.g., comorbidities, financial constraints, psychological issues), practitioner factors (e.g., poor knowledge of adherence, time constraints, poor communication skills and patient-doctor working alliance) and system factors (e.g., medication costs, lack of clinical monitoring, drug side effects). Non-adherence is associated with adverse health outcomes and increased costs of healthcare. A framework, based on a multidisciplinary approach, for addressing non-adherence, including managing the statin-intolerant patient, is presented. Conclusions: Nonadherence to statins is a significant issue for the prevention and treatment of cardiovascular disease. Increased awareness of the causes and solutions for overcoming non-adherence, including safer prescribing, improvement in physician-patient alliance and reduction in drug costs, will enhance the cost-effectiveness of the use of statins and significantly improve patient care and outcomes.
引用
收藏
页码:2973 / 2985
页数:13
相关论文
共 105 条
  • [1] Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients
    Ahmed, Waqas
    Khan, Naseer
    Glueck, Charles J.
    Pandey, Suman
    Wang, Ping
    Goldenberg, Naila
    Uppal, Muhammad
    Khanal, Suraj
    [J]. TRANSLATIONAL RESEARCH, 2009, 153 (01) : 11 - 16
  • [2] Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study
    Al-Omran, Mohammed
    Mamdani, Muhammad M.
    Lindsay, Thomas F.
    Melo, Magda
    Juurlink, David N.
    Verma, Subodh
    [J]. JOURNAL OF VASCULAR SURGERY, 2008, 48 (03) : 607 - 612
  • [3] Nurse case management of hypercholesterolemia in patients with coronary heart disease: Results of a randomized clinical trial
    Allen, JK
    Blumenthal, RS
    Margolis, S
    Young, DR
    Miller, ER
    Kelly, K
    [J]. AMERICAN HEART JOURNAL, 2002, 144 (04) : 678 - 686
  • [4] [Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action
  • [5] Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance
    Backes, James M.
    Venero, Carmelo V.
    Gibson, Cheryl A.
    Ruisinger, Janelle F.
    Howard, Patricia A.
    Thompson, Paul D.
    Moriarty, Patrick M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2008, 42 (03) : 341 - 346
  • [6] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [7] Health promotion by social cognitive means
    Bandura, A
    [J]. HEALTH EDUCATION & BEHAVIOR, 2004, 31 (02) : 143 - 164
  • [8] Health psychology: Mapping biobehavioral contributions to health and illness
    Baum, A
    Posluszny, DM
    [J]. ANNUAL REVIEW OF PSYCHOLOGY, 1999, 50 : 137 - 163
  • [9] Getting it right: why bother with patient-centred care?
    Bauman, AE
    Fardy, HJ
    Harris, PG
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2003, 179 (05) : 253 - 256
  • [10] Colesevelam HCl: a non-systemic lipid-altering drug
    Bays, H
    Dujovne, C
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) : 779 - 790